Iovance Biotherapeutics, Inc. (LON: 0JDK)
London
· Delayed Price · Currency is GBP · Price in USD
5.86
-0.09 (-1.55%)
Jan 23, 2025, 2:44 PM BST
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $58.56M USD in the quarter ending September 30, 2024, with 12,385.07% growth. This brings the company's revenue in the last twelve months to $90.86M, up 12,751.20% year-over-year. In the year 2023, Iovance Biotherapeutics had annual revenue of $1.19M.
Revenue (ttm)
$90.86M
Revenue Growth
+12,751.20%
P/S Ratio
n/a
Revenue / Employee
$163.12K
Employees
557
Market Cap
1.48B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Iovance Biotherapeutics News
- 5 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 12 days ago - Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga
- 14 days ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 20 days ago - Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outlook - GuruFocus
- 20 days ago - Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - The Motley Fool
- 4 weeks ago - Iovance Biotherapeutics Inc (IOVA) Announces Inducement Stock Options for New Employees - GuruFocus
- 4 weeks ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire